Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 19853481)

1.

Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis.

Lin Y, Ritchea S, Logar A, Slight S, Messmer M, Rangel-Moreno J, Guglani L, Alcorn JF, Strawbridge H, Park SM, Onishi R, Nyugen N, Walter MJ, Pociask D, Randall TD, Gaffen SL, Iwakura Y, Kolls JK, Khader SA.

Immunity. 2009 Nov 20;31(5):799-810. doi: 10.1016/j.immuni.2009.08.025. Epub 2009 Oct 22.

2.

IL-10 restrains IL-17 to limit lung pathology characteristics following pulmonary infection with Francisella tularensis live vaccine strain.

Slight SR, Monin L, Gopal R, Avery L, Davis M, Cleveland H, Oury TD, Rangel-Moreno J, Khader SA.

Am J Pathol. 2013 Nov;183(5):1397-404. doi: 10.1016/j.ajpath.2013.07.008. Epub 2013 Sep 3.

3.

IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection.

Roberts LM, Davies JS, Sempowski GD, Frelinger JA.

Vaccine. 2014 Jun 17;32(29):3595-603. doi: 10.1016/j.vaccine.2014.05.013. Epub 2014 May 14.

4.

Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.

Skyberg JA, Rollins MF, Samuel JW, Sutherland MD, Belisle JT, Pascual DW.

Infect Immun. 2013 Sep;81(9):3099-105. doi: 10.1128/IAI.00203-13. Epub 2013 Jun 17.

5.

Lung CD4-CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain.

Cowley SC, Meierovics AI, Frelinger JA, Iwakura Y, Elkins KL.

J Immunol. 2010 May 15;184(10):5791-801. doi: 10.4049/jimmunol.1000362. Epub 2010 Apr 14.

6.

IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination.

Gopal R, Lin Y, Obermajer N, Slight S, Nuthalapati N, Ahmed M, Kalinski P, Khader SA.

Eur J Immunol. 2012 Feb;42(2):364-73. doi: 10.1002/eji.201141569. Epub 2011 Dec 20.

7.

Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis.

Kirimanjeswara GS, Golden JM, Bakshi CS, Metzger DW.

J Immunol. 2007 Jul 1;179(1):532-9.

8.

Differing effects of interleukin-10 on cutaneous and pulmonary Francisella tularensis live vaccine strain infection.

Metzger DW, Salmon SL, Kirimanjeswara G.

Infect Immun. 2013 Jun;81(6):2022-7. doi: 10.1128/IAI.00024-13. Epub 2013 Mar 25.

9.

Th17 cytokines in recall responses against Francisella tularensis in humans.

Paranavitana C, Zelazowska E, DaSilva L, Pittman PR, Nikolich M.

J Interferon Cytokine Res. 2010 Jul;30(7):471-6. doi: 10.1089/jir.2009.0108.

PMID:
20626289
10.

IL-17 in protective immunity to intracellular pathogens.

Khader SA, Gopal R.

Virulence. 2010 Sep-Oct;1(5):423-7. doi: 10.4161/viru.1.5.12862. Review.

12.

Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.

Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH.

PLoS Pathog. 2013;9(4):e1003264. doi: 10.1371/journal.ppat.1003264. Epub 2013 Apr 4.

13.
14.

Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.

Kurtz SL, Foreman O, Bosio CM, Anver MR, Elkins KL.

Infect Immun. 2013 Feb;81(2):585-97. doi: 10.1128/IAI.01249-12. Epub 2012 Dec 10.

15.

Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain.

Sanapala S, Yu JJ, Murthy AK, Li W, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP.

Infect Immun. 2012 Jun;80(6):2177-85. doi: 10.1128/IAI.00036-12. Epub 2012 Apr 9.

16.

Late developmental plasticity in the T helper 17 lineage.

Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT.

Immunity. 2009 Jan 16;30(1):92-107. doi: 10.1016/j.immuni.2008.11.005.

19.

Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections.

Henry T, Kirimanjeswara GS, Ruby T, Jones JW, Peng K, Perret M, Ho L, Sauer JD, Iwakura Y, Metzger DW, Monack DM.

J Immunol. 2010 Apr 1;184(7):3755-67. doi: 10.4049/jimmunol.0902065. Epub 2010 Feb 22.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk